Solid Biosciences receives Nasdaq deficiency notice for bid price below $1.00

Solid Biosciences Inc.

Received deficiency letter on May 31, 2022 for failing to meet $1.00 minimum bid price requirement over 30 consecutive business days.
Company has 180 calendar days, until November 28, 2022, to regain compliance by closing at $1.00 or more for 10 consecutive days.
If not compliant by November 28, may transfer to Nasdaq Capital Market or consider a reverse stock split to cure deficiency.
There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.